San Diego Skin, Inc.
La Jolla, California, 92037, United States
NCT Number: NCT05508945
Interventional Study of the novel clinical application of SERI surgical silk scaffold affixed with dermaFLEX medical adhesive as a wound dressing, compared to two separate current standard of care for surgical incision closure devices: Prineo Dermabond and 3M Steri-Strip. Both components of the silk wound dressing prototype are FDA approved materials for other indications. This study seeks to gain insight of functionality of silk as a wound coverage material and determine variations of clinical outcomes in comparison to the synthetic mesh/cyanoacrylate device (Prineo Dermabond) and the nonwoven rayon/acrylate device (3M Steri-Strip) commonly implemented as a surgical wound dressing.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
La Jolla, California, 92037, United States
Participants for the study will be selected from a population of patients who have voluntarily sought out and consented to cosmetic and/or reconstructive surgery performed by M. Mark Mofid M.D. Patients who request and consent to procedures named in the protocol will be considered for eligibility of participation. Dr. Mofid will make the final determination after a thorough clinical evaluation of the patients medical information. Participants undergoing procedures that result in a single continuous surgical incision will receive the either Prineo Dermabond closure device or 3M Steri-Strip surgical incision closure device on 50% of the surgical incision, and the SERI Scaffold/ dermaFLEX combination on the remaining 50% of the incision. An automated randomization app will be used to determine which side, left or right, will receive each dressing. For an abdominoplasty, the incision typically extends from hip to hip, across the lower abdomen. For this procedure, the Prineo Dermabond or 3M Steri-Strip will be applied from the center of the incision: the belly button, and to the end of the incision, or hip, of the randomly determined side. The SERI Scaffold and dermaFLEX adhesive will be placed on the opposite side of the incision. For procedures that result in separate incisions, such as Breast Reductions, one breast will receive the Prineo Dermabond or 3M Steri-Strip coverage, while the other breast will receive the SERI Scaffold w/ dermaFLEX coverage. The sides will be determined through an automated randomization app. The surgeon, Dr. Mofid, will be informed which side will receive each dressing immediately before the respective dressings are to be applied. The dressings will subsequently be compared and evaluated during post-operative visits. Participants will complete a questionnaire at each designated post-operative visit and answers will be documented.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry
SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision
Other names: SERI surgical scaffold
non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
Time frame: 3 days post operation, 7 days post operation, 14 days post operation, 28 days post operation, 42 days post operation
Participants will self report symptoms of Contact Dermatitis surrounding the treated area quantified on a scaling system of 0-10 based upon the following criteria: Skin Discomfort, Skin Irritation, and Skin Itching.
The Principal Investigator will determine the clinical appearance of Contact Dermatitis surrounding the treated area quantified on a scaling system of 0-10 based upon the following criteria: Skin Rash and Skin Redness
Time frame: 3 days post operation, 7 days post operation, 14 days post operation
Participants will be evaluated by the Principal Investigator for signs of detached or displaced wound dressings. Participants will self report spontaneous detachment of wound dressing prior to anticipated dressing removal, scheduled 14 days post-operation. The results will be quantified by a measure of "Yes" or "No".
Time frame: 3 days post operation, 7 days post operation, 14 days post operation, 28 days post operation, 42 days post operation
The Principal Investigator will evaluate presence of infection at the surgical site based upon the standard clinical evidence of infection. The results will be quantified by a measure of "Yes" or "No".
Mehrdad Mark Mofid
Other
Silk Scaffold Surgical Incision Dressing Interventional Study
Acronym: SSSID
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02992951
Bacterial Infections, Bacterial Infections and Mycoses
Hull, East Riding of Yorkshire, United Kingdom
View Trial DetailsNCT06228729
Abdominal Surgery, Electroencephalogram
Seoul, South Korea
View Trial DetailsNCT05028816
Surgical Incision, Surgical Wound
Dallas, Texas, United States
View Trial DetailsNCT05296928
Gynecologic Surgery, Neurologic Manifestations
Adana, Turkey (Türkiye)
View Trial Details